Apply to trial NCT06499857

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 3Drug trial

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening